The Asia Pacific Spinal Muscular Atrophy Treatment Market would witness market growth of 19.4% CAGR during the forecast period (2022-2028).
Survival motor neuron gene 2 (SMN2), often known as the SMA backup gene, is a second gene that is present in all people with SMA in at least one and frequently numerous copies. Although SMN2 also creates SMN protein, the body can only utilize a limited portion of this protein. Numerous therapies that increase the usability of SMN protein target the SMN2 gene. Other SMN-enhancing methods directly replace or correct the mutated SMN1 gene.
Considering motor neurons are the cells most severely impacted by SMA, neuroprotective measures directed at this group of neurons may be successful, especially when combined with SMN-restoring therapy. One of the main symptoms of SMA type 2/3 is repeated nerve conduction and increased fatigability investigations reveal a decline, indicating that neuromuscular junction (NMJ) dysfunction may be significantly contributing to fatigability.
Therefore, pyridostigmine, an acetylcholinesterase inhibitor commonly recommended for myasthenia gravis, is presently being studied in phase II clinical trials to determine its impact on the efficiency of cholinergic transmission. According to early observations, pyridostigmine decreases patient fatigability and therefore, is considered a potential supplementary therapy.
Several studies were conducted in this region to figure out the psychosocial impacts of SMA on patients, families, and caretakers. More than half of the participants reported experiencing stress, and the majority of the caregivers reported experiencing anxiety. This is consistent with earlier studies that reported the great emotional costs associated with living with SMA. This may be because getting psychological counseling is culturally stigmatized in Asia, where people are taught to keep their emotions to themselves.
The China market dominated the Asia Pacific Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $523.6 million by 2028. The Japan market is estimated to grow a CAGR of 18.6% during (2022 - 2028). Additionally, The India market would experience a CAGR of 20.1% during (2022 - 2028).
Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Spinal Muscular Atrophy Treatment Market is Projected to reach USD 11.4 Billion by 2028, at a CAGR of 17.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
By Type
By Route of Administration
By Treatment Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
